Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marianne and Marcus Wallenberg Foundation (2015.0125)
UCLH Biomedical Research Centre
Svenska Forskningsrådet Formas
the Strategic Research Area MultiPark
Swedish Alzheimer Foundation (AF-939932)
Skåne University Hospital foundation (2020-O000028)
Regionalt Forskningsstöd (2020-0314)
Swedish federal government under the ALF agreement (2018-Projekt0279)
Race Against Dementia
Center for Medical Innovation
Stohnes Gamla Tjänarinnor
Received: 2 March 2021
Accepted: 9 July 2021
First Online: 13 August 2021
: All participants gave written informed consent to participate in the study. Ethical approval was given by the regional ethics committee at Lund University, Sweden. PET imaging procedures were approved by the Radiation protection committee at Skåne University Hospital and by the Swedish Medical Products Agency.
: Not applicable.
: RO is an associate editor at Alzheimer’s Research & Therapy. FB is a consultant to Biogen Idec, Merck-Serono, Novartis, Roche, IXICO Ltd, GeNeuro, and Combinostics. He received grants for Amyloid imaging for the Prevention of Alzheimer Disease (Innovative Medicines Initiative), European Progression Of Neurological Disease (H2020), UK Multiple Sclerosis Society, Dutch Multiple Sclerosis Society, National Institute Health Research University College London Biomedical Research Centre. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche.